13.12.2023 • NewsBASFspecialty aminesinvestment

BASF Completes Geismar Specialty Amines Expansion

BASF has completed its capacity expansion for key specialty amines manufactured at its US site in Geismar, Louisiana. The project, announced in June 2022, allows the company to increase production of polyetheramines and amine catalysts marketed under the Baxxodur and Lupragen brands.

“This project represents our commitment to growth in the Americas market,” said Kevin Anderson, BASF's vice president, Business Management Amines, Acetylenics and Carbonyl Derivatives, Chemical Intermediates, North America. “Our Geismar site was the ideal location for this expansion thanks to its existing infrastructure and skilled workforce.”

BASF’s Baxxodur portfolio is utilized by customers as highly efficient curing agents and chain extenders in epoxy and polyurea applications for the wind, electrical, composites, adhesives and flooring industries.

BASF’s Lupragen products are highly efficient amine catalysts for Polyurethanes (PU). Those catalysts are typically tertiary amines, which are required to facilitate the reaction of the main components – isocyanate and polyol. Depending on the choice of catalyst, the polyurethane forming process can be controlled to enhance the gelling or blowing reaction.

© BASF
© BASF

Company

Logo:

BASF AG

Carl-Bosch-Straße 38
67056 Ludwigshafen
Germany

Company contact







Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.